sur Newron Pharmaceuticals S.p.A. (isin : IT0004147952)
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Newron Pharmaceuticals S.p.A. will host its 2024 Investor Day on June 25, 2024 in New York City. The event begins at 9:00 AM EDT and will be available via live webcast. This session will focus on the company's evenamide program for treating treatment-resistant schizophrenia.
Leading experts including Dr. Anthony Grace from the University of Pittsburgh, Dr. John Kane from Hofstra/Northwell, and Dr. Stephen R. Marder from UCLA, will present their findings. They will review Phase III data and discuss new neurobiological concepts and the unmet needs in treating schizophrenia.
CEO Stefan Weber and Chief Medical Officer Ravi Anand of Newron will also provide updates on evenamide’s clinical and registration program. The event is open to institutional investors, business partners, analysts and media representatives. Pre-registration is required for attendance.
Access to the live webcast and international dial-in options are available. The webcast will be archived on Newron’s website for one month post-event.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Newron Pharmaceuticals S.p.A.